NeuBase Therapeutics changes fiscal year-end from Sept 30 to Dec 31 effective 2023

NeuBase Therapeutics, Inc.

Board approved change on April 21, 2023, aligning fiscal year with calendar year.
Fiscal year beginning Jan 1, 2023 will end Dec 31, 2023; transitional 10-QT for Oct-Dec 2022.
Reason: better alignment with the Company's planning cycles.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NeuBase Therapeutics, Inc.: Changed fiscal year end from September 30 to December 31, effective for the year ending December 31, 2023 (effective 2023-12-31).

Change: fiscal year change
Effective: 2023-12-31

Exact text from the filing

On April 21, 2023, the Board of Directors (the “Board”) of NeuBase Therapeutics, Inc. (the “Company”) approved a change in the Company’s fiscal year from the twelve months beginning October 1 and ending September 30 to the twelve months beginning January 1 and ending December 31, which will be effective for the year ending December 31, 2023.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001558370-23-006520

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.